Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat

Surgical Innovation

Volumn 16, Issue 4, 2009, Pages 299-305

  Buyne, Otmar R ^a   Van Goor, Harry ^a   Verweij, Paul E ^a   Bleichrodt, Robert P ^a   Hendriks, Thijs ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activator; Intra abdominal abscess; Rat model; Recombinant tissue type plasminogen; Secondary peritonitis

Indexed keywords

ALTEPLASE;

ABDOMINAL ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DEBRIDEMENT; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EARLY INTERVENTION; INFECTION PREVENTION; INFLAMMATION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; RAT;

ABDOMINAL ABSCESS; ANIMALS; FIBRINOLYTIC AGENTS; PERITONITIS; RATS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 76149119490     PISSN: 15533506     EISSN: None     Source Type: Journal    
DOI: 10.1177/1553350609355807     Document Type: Article

References (29)

1. Boermeester MA Surgical approaches to peritonitis. Br J Surg. 2007 ; 94: 1317-1318.
2. Chong AJ, Dellinger EP Current treatment of intraabdominal infections. Surg Technol Int. 2005 ; 14: 29-33.
3. Lamme B., Boermeester MA, Belt EJ, van Till JW, Gouma DJ, Obertop H. Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg. 2004 ; 91: 1046-1054.
4. Schein M. Surgical management of intra-abdominal infection: is there any evidence ? Langenbecks Arch Surg. 2002 ; 387: 1-7.
5. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med. 2003 ; 31: 2228-2237.
6. Marshall JC Intra-abdominal infections. Microbes Infect. 2004 ; 6: 1015-1025.
7. Sirinek KR Diagnosis and treatment of intra-abdominal abscesses. Surg Infect (Larchmt). 2000 ; 1: 31-38.
8. Rotstein OD, Kao J. Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. J Infect Dis. 1988 ; 158: 766-772.
9. van Goor H., de Graaf JS, Kooi K., et al. Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. J Am Coll Surg. 1994 ; 179: 407-411.
10. Buyne OR, Bleichrodt RP, Verweij PE, Groenewoud HM, van Goor H., Hendriks T. A peritonitis model with low mortality and persisting intra-abdominal abscesses. Int J Exp Pathol. 2006 ; 87: 361-368.
11. Buyne OR, Bleichrodt RP, van Goor H., Verweij PE, Hendriks T. Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. Int J Colorectal Dis. 2007 ; 22: 819-825.
12. Buyne OR, van GH, Bleichrodt RP, Verweij PE, Hendriks T. Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. Surgery. 2008 ; 144: 66-73.
13. Hartl WH, Wolf H., Schneider CP, Kuchenhoff H., Jauch KW Secular trends in mortality associated with new therapeutic strategies in surgical critical illness. Am J Surg. 2007 ; 194: 535-541.
14. van Goor H., de Graaf JS, Kooi K., Bleichrodt RP Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator. J Am Coll Surg. 1995 ; 181: 38-42.
15. Buyne OR, Bleichrodt RP, van GH, Verweij PE, Hendriks T. Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis. Br J Surg. 2008 ; 95: 1287-1293.
16. Buyne OR, Bleichrodt RP, de Man BM, et al. Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis. Surgery. 2009 ; 146: 939-946.
17. Hau T., Nishikawa RA, Phuangsab A. The effect of bacterial trapping by fibrin on the efficacy of systemic antibiotics in experimental peritonitis. Surg Gynecol Obstet. 1983 ; 157: 252-256.
18. van Goor H. In vitro studies on the effect of recombinant tissue plasminogen activator on the rat fibrinolytic system. In: Fibrinolytic Therapy in Generalized Peritonitis to Prevent Intra-abdominal Abscess Formation [dissertation]. Nijmegen, The Netherlands: Radboud University Nijmegen Medical Center ; 1996: 125-134.
19. van Goor H., Bom VJ, van der MJ, et al. Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model. Eur Surg Res. 1996 ; 28: 287-294.
20. Khurrum BM, Hua ZR, Batista O., et al. Percutaneous postoperative intra-abdominal abscess drainage after elective colorectal surgery. Tech Coloproctol. 2002 ; 6: 159-164.
21. Lamme B., Boermeester MA, Reitsma JB, Mahler CW, Obertop H., Gouma DJ Meta-analysis of relaparotomy for secondary peritonitis. Br J Surg. 2002 ; 89: 1516-1524.
22. Renckens R., Roelofs JJ, Florquin S., et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol. 2006 ; 177: 1189-1196.
23. Faist E., Schinkel C., Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg. 1996 ; 20: 454-459.
24. Damazo AS, Yona S., Flower RJ, Perretti M., Oliani SM Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis. J Immunol. 2006 ; 176: 4410-4418.
25. Blot S., De Waele JJ Critical issues in the clinical management of complicated intra-abdominal infections. Drugs. 2005 ; 65: 1611-1620.
26. Rau B., Kruger CM, Schilling MK Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg. 2004 ; 389: 134-144.
27. Sutton CD, Marshall LJ, Williams N., Berry DP, Thomas WM, Kelly MJ Colo-rectal anastomotic leakage often masquerades as a cardiac complication. Colorectal Dis. 2004 ; 6: 21-22.
28. Bell WR Present-day thrombolytic therapy: therapeutic agents-pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002 ; 3 (suppl 2). S34 - S44.
29. Deitcher SR, Jaff MR Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med. 2002 ; 3 (suppl 2). S25 - S33.